Search Results

There are 9433 results for: content related to: A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer

  1. Physicochemical properties of epidermal growth factor receptor inhibitors and development of a nanoliposomal formulation of gefitinib

    Journal of Pharmaceutical Sciences

    Volume 101, Issue 8, August 2012, Pages: 2763–2776, Brian J. Trummer, Vandana Iyer, Sathy V. Balu-Iyer, Robert O'Connor and Robert M. Straubinger

    Version of Record online : 11 MAY 2012, DOI: 10.1002/jps.23180

  2. You have free access to this content
    Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung


    Volume 118, Issue 4, 15 February 2012, Pages: 1032–1039, Gilberto de Lima Lopes Jr., Joel E. Segel, Daniel S. W. Tan, Young K. Do, Tony Mok and Eric A. Finkelstein

    Version of Record online : 26 JUL 2011, DOI: 10.1002/cncr.26372

  3. You have free access to this content
    Gefitinib and chemotherapy combination studies in five novel human non small cell lung cancer xenografts. Evidence linking EGFR signaling to gefitinib antitumor response

    International Journal of Cancer

    Volume 120, Issue 7, 1 April 2007, Pages: 1579–1590, Jean-Gabriel Judde, Magali Rebucci, Nicolas Vogt, Patricia de Cremoux, Alain Livartowski, Alain Chapelier, Carine Tran-Perennou, Karine Boye, Rémy Defrance, Marie-France Poupon and Rui-Alberto Bras-Gonçalves

    Version of Record online : 4 JAN 2007, DOI: 10.1002/ijc.22364

  4. You have free access to this content
    Establishment of a human non-small cell lung cancer cell line resistant to gefitinib

    International Journal of Cancer

    Volume 116, Issue 1, 10 August 2005, Pages: 36–44, Fumiaki Koizumi, Tatsu Shimoyama, Fumiko Taguchi, Nagahiro Saijo and Kazuto Nishio

    Version of Record online : 10 MAR 2005, DOI: 10.1002/ijc.20985

  5. You have full text access to this Open Access content
    Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors

    Cancer Science

    Volume 103, Issue 11, November 2012, Pages: 1946–1954, Kunihiko Minakata, Fumiyuki Takahashi, Takeshi Nara, Muneaki Hashimoto, Ken Tajima, Akiko Murakami, Fariz Nurwidya, Suzu Yae, Fumiaki Koizumi, Hiroyuki Moriyama, Kuniaki Seyama, Kazuto Nishio and Kazuhisa Takahashi

    Version of Record online : 14 SEP 2012, DOI: 10.1111/j.1349-7006.2012.02408.x

  6. You have free access to this content
    Gefitinib–phenytoin interaction is not correlated with the 14C-erythromycin breath test in healthy male volunteers

    British Journal of Clinical Pharmacology

    Volume 68, Issue 2, August 2009, Pages: 226–237, Stephanie Chhun, Celine Verstuyft, 1 Nathalie Rizzo-Padoin, 2 Guy Simoneau, Laurent Becquemont, 1 Ilana Peretti, 2 Alan Swaisland, 3 Robert Wortelboer, 4 Jean Francois Bergmann and Stephane Mouly

    Version of Record online : 5 MAY 2009, DOI: 10.1111/j.1365-2125.2009.03438.x

  7. You have full text access to this OnlineOpen article
    Survival of patients with advanced lung adenocarcinoma before and after approved use of gefitinib in China

    Thoracic Cancer

    Volume 6, Issue 5, September 2015, Pages: 636–642, Yu-Tao Liu, Xue-Zhi Hao, Jun-Ling Li, Xing-Sheng Hu, Yan Wang, Zi-Ping Wang, Hong-Yu Wang, Bin Wang, Xiao-Hong Han, Xiang-Ru Zhang and Yuan-Kai Shi

    Version of Record online : 21 MAY 2015, DOI: 10.1111/1759-7714.12267

  8. You have full text access to this Open Access content
    Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis

    Journal of Cellular and Molecular Medicine

    Volume 14, Issue 1-2, January-February 2010, Pages: 51–69, Luis Paz-Ares, Denis Soulières, Ivan Melezínek, Joachim Moecks, Lorenz Keil, Tony Mok, Rafael Rosell and Barbara Klughammer

    Version of Record online : 8 DEC 2009, DOI: 10.1111/j.1582-4934.2009.00991.x

  9. You have full text access to this OnlineOpen article
    An Apoferritin-based Drug Delivery System for the Tyrosine Kinase Inhibitor Gefitinib

    Advanced Healthcare Materials

    Volume 4, Issue 18, December 30, 2015, Pages: 2816–2821, Anchala I. Kuruppu, Lei Zhang, Hilary Collins, Lyudmila Turyanska, Neil R. Thomas and Tracey D. Bradshaw

    Version of Record online : 23 NOV 2015, DOI: 10.1002/adhm.201500389

  10. You have free access to this content
    Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib

    International Journal of Cancer

    Volume 123, Issue 12, 15 December 2008, Pages: 2939–2949, Tiziana Servidei, Anna Riccardi, Simona Mozzetti, Cristiano Ferlini and Riccardo Riccardi

    Version of Record online : 19 SEP 2008, DOI: 10.1002/ijc.23902

  11. You have full text access to this Open Access content
    Suppression of surfactant protein A by an epidermal growth factor receptor tyrosine kinase inhibitor exacerbates lung inflammation

    Cancer Science

    Volume 99, Issue 8, August 2008, Pages: 1679–1684, Akira Inoue, Hong Xin, Takuji Suzuki, Masahiko Kanehira, Yoshio Kuroki, Tatsuro Fukuhara, Toshiaki Kikuchi, Makoto Maemondo, Toshihiro Nukiwa and Yasuo Saijo

    Version of Record online : 14 AUG 2008, DOI: 10.1111/j.1349-7006.2008.00857.x

  12. Single-arm phase II study of multiagent concurrent chemoradiotherapy and gefitinib in locoregionally advanced squamous cell carcinoma of the head and neck

    Head & Neck

    Volume 34, Issue 11, November 2012, Pages: 1517–1523, Cristina P. Rodriguez, David J. Adelstein, Lisa A. Rybicki, Jerrold P. Saxton, Robert R. Lorenz, Benjamin G. Wood, Joseph Scharpf and Denise I. Ives

    Version of Record online : 16 DEC 2011, DOI: 10.1002/hed.21971

  13. You have free access to this content
    Gefitinib Inhibits the Proliferation of Pancreatic Cancer Cells via Cell Cycle Arrest

    The Anatomical Record

    Volume 292, Issue 8, August 2009, Pages: 1122–1127, Xiaohua Zhou, Maqing Zheng, Fang Chen, Yunxia Zhu, Wei Yong, Haiyan Lin, Yujie Sun and Xiao Han

    Version of Record online : 30 JUL 2009, DOI: 10.1002/ar.20938

  14. Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia

    European Journal of Haematology

    Volume 81, Issue 5, November 2008, Pages: 344–353, Elin Lindhagen, Anna Eriksson, Malin Wickström, Katarina Danielsson, Birgitta Grundmark, Roger Henriksson, Peter Nygren, Anna Åleskog, Rolf Larsson and Martin Höglund

    Version of Record online : 10 JUL 2008, DOI: 10.1111/j.1600-0609.2008.01120.x

  15. You have free access to this content
    Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01)


    Volume 118, Issue 24, 15 December 2012, Pages: 6234–6242, Jong-Mu Sun, Ki Hyeong Lee, Sang-we Kim, Dae Ho Lee, Young Joo Min, Hwan Jung Yun, Hoon Kyo Kim, Hong Suk Song, Yeul Hong Kim, Bong-Seog Kim, In Gyu Hwang, Keehyun Lee, Sook Jung Jo, Jae Won Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn and for the Korean Cancer Study Group (KCSG)

    Version of Record online : 6 JUN 2012, DOI: 10.1002/cncr.27630

  16. Valproic acid sensitizes human glioma cells to gefitinib-induced autophagy

    IUBMB Life

    Volume 67, Issue 11, November 2015, Pages: 869–879, Cheng-Yi Chang, Jian-Ri Li, Chih-Cheng Wu, Yen-Chuan Ou, Wen-Ying Chen, Yu-Hsiang Kuan, Wen-Yi Wang and Chun-Jung Chen

    Version of Record online : 21 OCT 2015, DOI: 10.1002/iub.1445

  17. Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective

    Asia-Pacific Journal of Clinical Oncology

    Volume 8, Issue 1, March 2012, Pages: 53–61, Sumitra THONGPRASERT, Sirana TINMANEE and Unchalee PERMSUWAN

    Version of Record online : 28 FEB 2012, DOI: 10.1111/j.1743-7563.2012.01528.x

  18. You have free access to this content
    Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer

    International Journal of Cancer

    Volume 107, Issue 6, 20 December 2003, Pages: 1030–1037, Satoru Shintani, Chunnan Li, Mariko Mihara, Nagaaki Terakado, Junya Yano, Koh-ichi Nakashiro and Hiroyuki Hamakawa

    Version of Record online : 12 SEP 2003, DOI: 10.1002/ijc.11437

  19. You have free access to this content
    Reversal of Multidrug Resistance by Gefitinib Via RAF1/ERK Pathway in Pancreatic Cancer Cell Line

    The Anatomical Record

    Volume 295, Issue 12, December 2012, Pages: 2122–2128, Zhi Xiao, Nianhua Ding, Guiqing Xiao, Shouman Wang, Yuhui Wu and Lili Tang

    Version of Record online : 21 AUG 2012, DOI: 10.1002/ar.22552

  20. You have free access to this content
    Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer


    Volume 106, Issue 9, 1 May 2006, Pages: 1917–1924, George Wilding, Patrick Soulie, Donald Trump, Ashis Das-Gupta and Eric Small

    Version of Record online : 27 MAR 2006, DOI: 10.1002/cncr.21831